ArticleMolecules (Basel, Switzerland)2026
Pharmacophore-Based QSAR Model of Multi Scaffolds as NAMPT Inhibitors & Scaffold Diversity Analysis.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
NAD+ plays crucial roles in various biological processe and its aberrant regulation has been suggested to be critical in the pathogenesis of diverse diseases. Intracellular NAD+ is synthesized largely from nicotinamide mononucleotide (NMN), which is the product of reaction catalyzed by nicotinamide phosphoribosyltransferase (NAMPT). Thus, the development of specific inhibitors targeting NAMPT has been suggested as a promising treatment strategy. In this study, we developed a pharmacophore-based QSAR model to discover novel NAMPT inhibitors based on diverse structural features. By virtual screening using the conformation model, we could identify eight novel active analogs having distinct pharmacophores. The biological activity of these candidates on cell viability were further examined. Our study proves the efficiency of our novel screening model and demonstrates its usefulness in the application of drug discovery process.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.